Inflammatix, Inc.
863 Mitten Road Suite 104
Burlingame, CA 94010
United States
Tel: (650) 443-3030
Website: https://inflammatix.com/
Email: info@inflammatix.com
About Inflammatix, Inc.
Inflammatix is developing an innovative point-of-care instrument platform to be used with a rapid (<30-minute) test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our HostDx test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions for better patient outcomes.
Dr. Tim Sweeney, Inflammatix Co-Founder and CEO TEDx Palo Alto: 'The power of reading the immune system to better diagnose disease'
14 articles with Inflammatix, Inc.
-
Inflammatix Appoints Dr. Kian Beyzavi as New Board Member
11/30/2021
Inflammatix announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors.
-
Inflammatix Announces Additional $12.1 Million Funding From BARDA for ViraBac EZ Acute Infection Test
11/18/2021
Inflammatix announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA).
-
Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)
11/11/2021
Inflammatix has awarded the company a Small Business Innovation Research (NIH SBIR) Direct-to-Phase II grant of $1.7 million.
-
Inflammatix Appoints Amy Boyle as Chief Operating Officer
4/15/2021
Inflammatix , a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021.
-
Money on the Move: March 10-16
3/17/2021
Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week. -
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
3/16/2021
Inflammatix , a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.
-
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
-
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
10/29/2020
Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care
-
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic That Predicts COVID-19 Severity Risk
9/29/2020
New Data Shows Inflammatix Machine Learning-Based Approach of Reading Immune System is Superior to IL-6 and Other Measures in Predicting Patients at High Risk for Severe COVID-19 BURLINGAME, Calif.--( BUSINESS WIRE )-- Inflammatix , a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads
-
New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System
3/4/2020
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response.
-
Inflammatix Wins AACC's Disruptive Technology Award For Its Rapid HostDx™ Tests
8/6/2019
Inflammatix, a molecular diagnostics company that is reimagining diagnostics, announced today that it has received the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.
-
Inflammatix Named a Finalist for AACC's Disruptive Technology Award For Its Rapid HostDx™ Tests
5/16/2019
Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.
-
Inflammatix to Present New Data at IDWeek 2018 Demonstrating Ability to Perform HostDx™ Fever Test to Rapidly Distinguish Bacterial from Viral Infections Across Multiple Laboratory Platforms
10/4/2018
Novel data-driven test reads the immune system response to help diagnose acute infections
-
Inflammatix Announces Appointment of Oliver Liesenfeld, M.D., as CMO
12/19/2017
Dr. Liesenfeld, a veteran of the diagnostics industry, comes to the company from Roche Molecular Diagnostics, where he served as chief medical officer since 2012.